CompanySTOKNasdaqBedford, MA

Stoke Therapeutics, Inc

Stoke Therapeutics develops antisense oligonucleotides using its TANGO platform to restore protein expression in haploinsufficiency disorders.

SEC EDGAR ClinicalTrials.gov stoketherapeutics.com

SCHEDULE 13GSep 30Latest SEC filing

Sep 25Latest story

September 2026

Stoke Therapeutics adds Alexander Cumbo to board after Kaye resignation

Sep 25PeopleStoke Therapeutics, Inc

August 2026

Stoke Therapeutics files $200 million at-the-market stock offering

Aug 3FinancingStoke Therapeutics, Inc

Stoke reports full EMPEROR enrollment, sets pre-NDA meeting and Q1 2027 filing start

Aug 3Quarterly updateStoke Therapeutics, Inc

June 2026

Stoke Therapeutics completes enrollment of 162-patient Phase 3 EMPEROR trial for zorevunersen

Jun 30Quarterly updateStoke Therapeutics, Inc zorevunersen